The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 analogues and, more recently, the dual GIP and GLP-3 receptor agonist retatrutide. https://antonelpa395017.jts-blog.com/37791313/glp-3-retatrutide-a-comparative-analysis